[Development of peptidic MERS-CoV entry inhibitors]

Area of Science:

• Virology
• Infectious Diseases
• Drug Discovery

Background:

• Middle East respiratory syndrome coronavirus (MERS-CoV), a SARS-like virus, emerged in 2012 and has caused high-mortality outbreaks.
• MERS-CoV infection relies on its S protein; the S1 subunit binds the DPP4 receptor, while the S2 subunit mediates membrane fusion via a six-helix bundle.

Purpose of the Study:

• To review recent advancements in developing peptidic entry inhibitors.
• To focus on inhibitors targeting the MERS-CoV S2 subunit's six-helix bundle formation.

Main Methods:

• Literature review of recent research on MERS-CoV entry inhibitors.
• Analysis of studies focusing on peptidic inhibitors targeting the MERS-CoV S2 subunit.

Main Results:

• The formation of a stable six-helix bundle by the MERS-CoV S2 subunit's HR1 and HR2 regions is crucial for viral entry.
• Blocking this six-helix bundle formation is a viable strategy to inhibit MERS-CoV cell entry.
• Recent progress has been made in developing peptidic inhibitors targeting this mechanism.

Conclusions:

• Peptidic inhibitors targeting the MERS-CoV S2 subunit represent a promising therapeutic strategy.
• Inhibition of the six-helix bundle formation effectively blocks MERS-CoV entry into host cells.
• Further research into these peptidic inhibitors could lead to effective treatments for MERS-CoV infections.